These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 16051949)

  • 1. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
    D'Amico AV; Chen MH; Roehl KA; Catalona WJ
    J Clin Oncol; 2005 Aug; 23(22):4975-9. PubMed ID: 16051949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?
    Loeb S; Roehl KA; Helfand BT; Kan D; Catalona WJ
    J Urol; 2010 Jan; 183(1):112-6. PubMed ID: 19913814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
    Bjerner J; Bratt O; Aas K; Albertsen PC; Fosså SD; Kvåle R; Lilja H; Müller C; Müller S; Stensvold A; Thomas O; Røe OD; Vickers A; Walz J; Carlsson SV; Oldenburg J
    Eur Urol; 2024 Jul; 86(1):20-26. PubMed ID: 37169639
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lopategui DM; Porto JG; Bhatia A; Titus R; Marcovich R; Shah HN
    J Endourol; 2024 Apr; ():. PubMed ID: 38545770
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.
    Van der Kwast TH; Bolla M; Van Poppel H; Van Cangh P; Vekemans K; Da Pozzo L; Bosset JF; Kurth KH; Schröder FH; Collette L;
    J Clin Oncol; 2007 Sep; 25(27):4178-86. PubMed ID: 17878474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
    Trock BJ; Han M; Freedland SJ; Humphreys EB; DeWeese TL; Partin AW; Walsh PC
    JAMA; 2008 Jun; 299(23):2760-9. PubMed ID: 18560003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CircSCAF8 promotes growth and metastasis of prostate cancer through the circSCAF8-miR-140-3p/miR-335-LIF pathway.
    He T; Tao W; Zhang LL; Wang BY; Li K; Lu HM; Tang GJ; He YD; Li LY
    Cell Death Dis; 2022 Jun; 13(6):517. PubMed ID: 35654787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of Prostate Specific Antigen variations in the last week of salvage radiotherapy for biochemical recurrence of prostate cancer after surgery: A practical approach.
    Vigna-Taglianti R; Boriano A; Gianello L; Melano A; Bergesio F; Merlotti AM; Reali A; Petrucci R; Russi EG
    Cancer Rep (Hoboken); 2020 Dec; 3(6):e1285. PubMed ID: 32881424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer.
    Luo Y; Li M; Qi H; Zhao J; Han Y; Lin Y; Hou Z; Jiang Y
    World J Surg Oncol; 2018 Jun; 16(1):107. PubMed ID: 29890979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
    García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
    Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidental prostate cancer diagnosed at radical cystoprostatectomy for bladder cancer: disease-specific outcomes and survival.
    Kaelberer JB; O'Donnell MA; Mitchell DL; Snow AN; Mott SL; Buatti JM; Smith MC; Watkins JM
    Prostate Int; 2016 Sep; 4(3):107-12. PubMed ID: 27689068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas.
    Waliszewski P
    Front Physiol; 2016; 7():34. PubMed ID: 26903883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
    Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
    Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
    Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
    Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of biochemical recurrence after primary localized therapy for prostate cancer.
    Darwish OM; Raj GV
    Front Oncol; 2012; 2():48. PubMed ID: 22655274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006.
    Zhu Y; Sorkin JD; Dwyer D; Groves C; Steinberger EK
    Prev Chronic Dis; 2011 Sep; 8(5):A114. PubMed ID: 21843417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens.
    Cho IC; Kwon WA; Kim JE; Joung JY; Seo HK; Chung J; Park WS; Lee KH
    J Korean Med Sci; 2011 Jun; 26(6):807-13. PubMed ID: 21655069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur.
    Audenet F; Seringe E; Drouin SJ; Comperat E; Cussenot O; Bitker MO; Rouprêt M
    World J Urol; 2012 Apr; 30(2):239-44. PubMed ID: 21638225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.